Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 436

1.

Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.

Koolen BB, Valdés Olmos RA, Elkhuizen PH, Vogel WV, Vrancken Peeters MJ, Rodenhuis S, Rutgers EJ.

Breast Cancer Res Treat. 2012 Aug;135(1):231-40. doi: 10.1007/s10549-012-2179-1. Epub 2012 Jul 28.

PMID:
22872522
2.
3.

Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.

Riegger C, Koeninger A, Hartung V, Otterbach F, Kimmig R, Forsting M, Bockisch A, Antoch G, Heusner TA.

Acta Radiol. 2012 Dec 1;53(10):1092-8. doi: 10.1258/ar.2012.110635. Epub 2012 Sep 22.

PMID:
23002144
4.

Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II-III breast cancer patients treated with neoadjuvant chemotherapy.

Koolen BB, Valdés Olmos RA, Vogel WV, Vrancken Peeters MJ, Rodenhuis S, Rutgers EJ, Elkhuizen PH.

Breast Cancer Res Treat. 2013 Sep;141(2):249-54. doi: 10.1007/s10549-013-2678-8. Epub 2013 Sep 4.

PMID:
24002735
5.

Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.

Dalus K, Reitsamer R, Holzmannhofer J, Rendl G, Pirich C, Kronberger C, Rettenbacher L.

Nuklearmedizin. 2011;50(1):33-8. doi: 10.3413/nukmed-0320-10-05.

PMID:
21336417
6.

18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.

Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G, Zhang J, Geng D.

Oncotarget. 2015 Oct 6;6(30):29388-95. doi: 10.18632/oncotarget.5001.

7.

Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.

Straver ME, Aukema TS, Olmos RA, Rutgers EJ, Gilhuijs KG, Schot ME, Vogel WV, Peeters MJ.

Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1069-76. doi: 10.1007/s00259-009-1343-2. Epub 2010 Feb 4.

8.

Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.

Aukema TS, Straver ME, Peeters MJ, Russell NS, Gilhuijs KG, Vogel WV, Rutgers EJ, Olmos RA.

Eur J Cancer. 2010 Dec;46(18):3205-10. doi: 10.1016/j.ejca.2010.07.034. Epub 2010 Aug 16.

PMID:
20719497
9.

Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.

Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ.

Breast Cancer. 2013 Apr;20(2):167-73. doi: 10.1007/s12282-011-0323-0. Epub 2012 Feb 7.

PMID:
22311581
10.

Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.

Hahn S, Hecktor J, Grabellus F, Hartung V, Pöppel T, Kimmig R, Forsting M, Antoch G, Heusner TA.

Acta Radiol. 2012 Jun 1;53(5):518-23. doi: 10.1258/ar.2012.110420. Epub 2012 Apr 30.

PMID:
22547387
11.

Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.

Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, Kondo T, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.

BMC Cancer. 2008 Jun 9;8:165. doi: 10.1186/1471-2407-8-165.

12.

Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Detection of axillary lymph node metastasis in breast cancer patients.

An YS, Lee DH, Yoon JK, Lee SJ, Kim TH, Kang DK, Kim KS, Jung YS, Yim H.

Nuklearmedizin. 2014;53(3):89-94. doi: 10.3413/Nukmed-0605-13-06. Epub 2013 Nov 13.

PMID:
24220324
13.

A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.

Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, Spano G, Luini A, Intra M, Veronesi P, Berrettini A, Paganelli G.

Ann Oncol. 2007 Mar;18(3):473-8. Epub 2006 Dec 12.

PMID:
17164229
14.

The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.

Choi WH, Yoo IR, O JH, Kim SH, Chung SK.

Br J Radiol. 2011 Jul;84(1003):593-9. doi: 10.1259/bjr/56324742. Epub 2010 Nov 16.

15.

Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.

Ergul N, Kadioglu H, Yildiz S, Yucel SB, Gucin Z, Erdogan EB, Aydin M, Muslumanoglu M.

Acta Radiol. 2015 Aug;56(8):917-23. doi: 10.1177/0284185114539786. Epub 2014 Jul 10.

PMID:
25013091
16.

Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.

Koolen BB, Valdés Olmos RA, Wesseling J, Vogel WV, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Vrancken Peeters MJ.

Ann Surg Oncol. 2013 Jul;20(7):2227-35. doi: 10.1245/s10434-013-2902-0. Epub 2013 Mar 1.

PMID:
23456316
17.

Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.

García Vicente AM, Soriano Castrejón A, Cruz Mora MÁ, Ortega Ruiperez C, Espinosa Aunión R, León Martín A, González Ageitos A, Van Gómez López O.

Rev Esp Med Nucl Imagen Mol. 2014 Jan-Feb;33(1):1-5. doi: 10.1016/j.remn.2013.03.005. Epub 2013 May 23.

18.

Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.

Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, Kimmig KR, Forsting M, Bockisch A, Antoch G, Stahl A.

Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1543-50. doi: 10.1007/s00259-009-1145-6. Epub 2009 May 5.

PMID:
19415270
19.

The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.

Ahn JH, Son EJ, Kim JA, Youk JH, Kim EK, Kwak JY, Ryu YH, Jeong J.

Acta Radiol. 2010 Oct;51(8):859-65. doi: 10.3109/02841851.2010.501342.

PMID:
20670083
20.

Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.

Seo MJ, Lee JJ, Kim HO, Chae SY, Park SH, Ryu JS, Ahn SH, Lee JW, Son BH, Gong GY, Moon DH.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):438-45. doi: 10.1007/s00259-013-2600-y. Epub 2013 Nov 6.

PMID:
24196918

Supplemental Content

Support Center